TLR3 Agonists as Vaccine Adjuvants
Idera has created a new class of synthetic double-stranded RNA-based compounds that act as agonists of TLR3.
Selected proprietary agonists have been shown to induce immune responses in cell-based assays and in vivo in preclinical models following systemic administration.
Potential applications of TLR3 agonists include use as vaccine adjuvants. Preclinical data showing the application of TLR3 agonists as vaccine adjuvants has been presented.